Abstract:Morphine tolerance remains a challenge in the management of chronic pain in the clinic. As shown in our previous study, the dopamine D2 receptor (D2DR) expressed in spinal cord neurons might be involved in morphine tolerance, but the underlying mechanisms remain to be elucidated. In the present study, selective spinal D2DR blockade attenuated morphine tolerance in mice by inhibiting phosphatidylinositol 3 kinase (PI3K)/serine–threonine kinase (Akt)-mitogen activated protein kinase (MAPK) signaling in a μ opioid receptor (MOR)-dependent manner. Levo-corydalmine (l-CDL), which exhibited micromolar affinity for D2DR in D2/CHO-K1 cell lines in this report and effectively alleviated bone cancer pain in our previous study, attenuated morphine tolerance in rats with chronic bone cancer pain at nonanalgesic doses. Furthermore, the intrathecal administration of l-CDL obviously attenuated morphine tolerance, and the effect was reversed by a D2DR agonist in mice. Spinal D2DR inhibition and l-CDL also inhibited tolerance induced by the MOR agonist DAMGO. l-CDL and a D2DR small interfering RNA (siRNA) decreased the increase in levels of phosphorylated Akt and MAPK in the spinal cord; these changes were abolished by a PI3K inhibitor. In addition, the activated Akt and MAPK proteins in mice exhibiting morphine tolerance were inhibited by a MOR antagonist. Intrathecal administration of a PI3K inhibitor also attenuated DAMGO-induced tolerance. Based on these results, l-CDL antagonized spinal D2DR to attenuate morphine tolerance by inhibiting PI3K/Akt-dependent MAPK phosphorylation through MOR. These findings provide insights into a more versatile treatment for morphine tolerance. By blocking dopamine receptors located in the spinal cord, a compound found in a traditional Chinese herbal medicine may help mitigate tolerance to morphine, a common problem among cancer patients who regularly take the opioid painkiller. A team led by Ji-Hua Liu and Bo-Yang Yu from China Pharmaceutical University in Nanjing had previously showed that inhibiting dopamine D2 receptors in spinal neurons prevented mice from developing morphine tolerance, but it wasn’t clear why. They have now demonstrated that blocking D2 receptors prevents the relay of cellular signals from morphine-binding “μ-opioid” receptors to mediators of drug tolerance. Levo-corydalmine, a compound isolated from the Asian Corydalis plant, binds and inhibits D2 receptors. When administered directly into the spinal cords of mice and rats, it blocked downstream signaling, reducing morphine tolerance.

Corydaline and l-tetrahydropalmatine attenuate morphine-induced conditioned place preference and the changes in dopamine D2 and GluA1 AMPA receptor expression in rats

Influence of l-tetrahydropalmatine on morphine-induced conditioned place preference

Selective Blockade of Spinal D2DR by Levo-Corydalmine Attenuates Morphine Tolerance Via Suppressing PI3K/Akt-MAPK Signaling in a MOR-dependent Manner

Inhibitory Effects of Processed Aconiti Tuber on Morphine-Induced Conditioned Place Preference in Rats

Pharmacological Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) As a Dual Selective MOR/KOR Ligand with Potential Applications in Treating Opioid Use Disorder.

Levo-tetrahydropalmatine Attenuates Methamphetamine Reward Behavior and the Accompanying Activation of ERK Phosphorylation in Mice

Effects of l -tetrahydropalmatine on locomotor sensitization to oxycodone in mice

Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

The effect of L-stepholidine, a novel extract of Chinese herb, on the acquisition, expression, maintenance, and re-acquisition of morphine conditioned place preference in rats.

Upregulation of HCN2 in ventral tegmental area is involved in morphine‐induced conditioned place preference in rats

Inhibition of Phosphodiesterase10a Attenuates Morphine-Induced Conditioned Place Preference.

Levo-tetrahydropalmatine attenuates oxycodone-induced conditioned place preference in rats.

Roles of levo-tetrahydropalmatine in modulating methamphetamine reward behavior

The Possible Involvement of Endogenous Ligands for Mu-, Delta- and Kappa-Opioid Receptors in Modulating Morphine-Induced CPP Expression in Rats

Dopamine D1 and D2 Receptors Mediate Analgesic and Hypnotic Effects of L-Tetrahydropalmatine in a Mouse Neuropathic Pain Model

Effects of the altered activity of δ-opioid receptor on the expression of glutamate transporter type 3 induced by chronic exposure to morphine.

Pharmacological Characterization and Therapeutic Potential for the Treatment of Opioid Abuse with ATPM-ET, an N-ethyl Substituted Aminothiazolomorphinan with Κ Agonist and Μ Agonist/antagonist Activity.

Morphine Withdrawal-Induced Hyperalgesia in Models of Acute and Extended Withdrawal Is Attenuated by l-Tetrahydropalmatine

The effects of penehyclidine hydrochloride on the withdrawal syndrome and conditioned place preference of morphine dependent rats

L-Tetrahydropalmatine alleviates mechanical hyperalgesia in models of chronic inflammatory and neuropathic pain in mice.

Role of MEK‐ERK Pathway in Morphine‐induced Conditioned Place Preference in Ventral Tegmental Area of Rats